The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 ...

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

Mosquitoes can tranmist dengue virus, which has already caused local cases in Florida in 2025... | Clinical And Molecular Dx ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

Longer, hotter summers and shifting weather patterns — fueled by a warming planet — are bringing about more than just sunshine and higher temperatures. Mosquitoes are thriving earlier and later and ...

The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects. The Centers for Disease Control and Prevention and the Food and ...